By Jocelyn Aspa
Digi International (NASDAQ:DGII) has announced the immediate availability of its patented Digi Data Logger, a wireless temperature monitoring and tracking solution for shipping perishable goods.
As quoted in the press release:
The Digi Data Logger, which is attached to the shipment packaging or pallet, or placed in direct contact with the product,
AVEO Pharmaceuticals, Staar Surgical, Vericel, PDL BioPharma, Natural Alternatives top the NASDAQ biotech stock list.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Dynavax Technologies saw its stock jump over 70 percent on Monday thanks to a favorable review from the US Food and Drug Administration advisory committee for their hepatitis B vaccine.
BriaCell Therapeutics announced the opening of a new clinical site in Florida and the appointment of Dr. Elizabeth Tan-Chiu as the clinical site’s principal investigator.
The Klein Law Firm announced a class action complaint filed on behalf of shareholders of Sinovac Biotech who purchased their shares between April 30, 2013 and May 16, 2017.
ImmunoPrecise announced the engagement of TerraMar Environmental Research to develop immune-contraceptive vaccines for overabundant wildlife populations.
GeoVax Labs announced that in collaboration with a variety of medical groups is collaborating for the advanced development of a preventive vaccine against Lassa hemorrhagic fever virus.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
BriaCell Therapeutics provided an update on their open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVax treating advanced breast cancer.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
Heat Biologics announced its subsidiary Pelican Therapeutics received the first tranche of a $15.2 million grant award.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
OncBioMune Pharmaceuticals obtained a patent from the Mexican Institute of Industrial Property protecting the intellectual rights of the company’s ProscaVax throughout Mexico until January 8, 2032.
OncBioMune Pharmaceuticals obtained a patent in Hong Kong for ProscaVax, the company’s immunotherapeutic cancer vaccine.